An AstraZeneca-Bristol Myers megamerger? Wall Street isn't thrilled.
An AstraZeneca-Bristol Myers megamerger? Wall Street isn't thrilled.
Bristol Myers Squibb
Bristol Myers Squibb (NYSE: BMY) is a global biopharmaceutical company with a strong oncology franchise (Opdivo, Yervoy, Reblozyl, Pomalyst, Empliciti), hematology, cardiovascular (Eliquis), and immunology (Sotyktu, Zeposia, deucravacitinib). BMS is investing in cell therapy, radiopharmaceuticals, and next-generation immuno-oncology platforms.
Company Info
Sector:Diversified Biopharmaceuticals
Headquarters:Princeton, New Jersey, USA
Founded:1887
Website:www.bms.com/
Recent News
BMS’ ‘big beat’ clouded by Cobenfy, heart disease data delays
BMS’ ‘big beat’ clouded by Cobenfy, heart disease data delays. Reported by BioSpace on 2026-07-30.
BMS, NVIDIA to build 'most powerful' AI factory
BMS, NVIDIA to build 'most powerful' AI factory.
Bristol Myers to build 'powerful' AI factory; Samsung Biologics bids for peptide maker
Bristol Myers Squibb announced it would build a 'powerful' AI factory, while Samsung Biologics bids for peptide maker PolyPeptide.
Bristol Myers reaches a crossroads as a make-or-break year takes shape
Bristol Myers Squibb enters a pivotal year with multiple late-stage readouts and strategic decisions that could reshape its growth trajectory through the back half of the decade.
Leadership Team
Christopher Boerner, Ph.D.
Chairman and Chief Executive Officer
David Elkins
Chief Financial Officer
Careers & Job Openings